William E. Winter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William E. Winter has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Neil S. Harris
Department of Pathology, Immunology and Laboratory Medicine, University of Florida , Gainesville, FL
5 shared publications Desmond Schatz
4 shared publicationsNeil S. Harris
Departments of Pathology, Immunology and Laboratory Medicine, Pediatrics, and Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA
4 shared publicationsIshwarlal Jialal
Veterans Affair Medical Center, Mather, CA, USA
3 shared publications- Ishwarlal Jialal
UC Davis School of Medicine, 2616 Hepworth Drive, Davis, CA 95618, USA
3 shared publications Donald S. Young
2 shared publications
Latest Publications
- Open Access
Hemoglobin—A Review of Structure, Mechanisms and Analysis in the Clinical Diagnostic Laboratory
This review focuses on the analysis of hemoglobin in the clinical laboratory with an emphasis on the structure–function relationships of hemoglobin and the various methodologies used for its measurement. In clinical laboratories, hemoglobin analysis may take on many forms. These include measuring the concentration of hemoglobin, as well as determining the percentage of oxyhemoglobin, deoxyhemoglobin and dyshemoglobins such as carboxyhemoglobin. There are also techniques available to estimate the oxygen affinity of hemoglobin. Hemoglobin separation techniques by means of electrophoresis or chromatography are essential in the diagnosis of hemoglobinopathies (such as sickle cell anemia) and thalassemias, where there is an imbalance in globin chain synthesis. Hemoglobin contains four globin subunits, which create a unique quaternary structure in which the oxygen affinity can be changed by allosteric modifiers, including oxygen itself. The heme iron-containing tetrapyrrole ring not only carries oxygen; it also controls the binding of oxygen to the other globin subunits. The organization and regulation of the globin genes are discussed to provide essential biological context for informed interpretation of clinical test results. Building on this foundation, selected hemoglobinopathies and thalassemias are highlighted to further illustrate structure–function relationships and their implications for diagnostic testing. However, an exhaustive analysis of hemoglobinopathies is beyond the intended scope of this review, which is not meant to be all-encompassing, as these subjects are extensively addressed in many textbooks and published articles and reviews.
Open AccessHemoglobin—A Review of Structure, Mechanisms and Analysis in the Clinical Diagnostic Laboratory
This review focuses on the analysis of hemoglobin in the clinical laboratory with an emphasis on the structure–function relationships of hemoglobin and the various methodologies used for its measurement. In clinical laboratories, hemoglobin analysis may take on many forms. These include measuring the concentration of hemoglobin, as well as determining the percentage of oxyhemoglobin, deoxyhemoglobin and dyshemoglobins such as carboxyhemoglobin. There are also techniques available to estimate the oxygen affinity of hemoglobin. Hemoglobin separation techniques by means of electrophoresis or chromatography are essential in the diagnosis of hemoglobinopathies (such as sickle cell anemia) and thalassemias, where there is an imbalance in globin chain synthesis. Hemoglobin contains four globin subunits, which create a unique quaternary structure in which the oxygen affinity can be changed by allosteric modifiers, including oxygen itself. The heme iron-containing tetrapyrrole ring not only carries oxygen; it also controls the binding of oxygen to the other globin subunits. The organization and regulation of the globin genes are discussed to provide essential biological context for informed interpretation of clinical test results. Building on this foundation, selected hemoglobinopathies and thalassemias are highlighted to further illustrate structure–function relationships and their implications for diagnostic testing. However, an exhaustive analysis of hemoglobinopathies is beyond the intended scope of this review, which is not meant to be all-encompassing, as these subjects are extensively addressed in many textbooks and published articles and reviews.
- Open Access
- 26 March 2026
- Published by Scilight Press Pty Ltd in International Journal of Clinical and Translational Medicine
- Vol. 2 (1) , 7
R Is for Rocket … or “Is ‘R’ … for the Strength of a Correlation?”
In assessing linear relationships between variables, the r value (aka–correlation coefficient) is insufficient by itself to determine if one measurement can be replaced by another measurement.
- 26 March 2026
- Published by Scilight Press Pty Ltd in International Journal of Clinical and Translational Medicine
- Vol. 2 (1) , 7
Open AccessR Is for Rocket … or “Is ‘R’ … for the Strength of a Correlation?”
In assessing linear relationships between variables, the r value (aka–correlation coefficient) is insufficient by itself to determine if one measurement can be replaced by another measurement.
- Open Access
- 15 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 710
Should Prediabetes Be Classified as a Treatable Disease?
Prediabetes is a serious and major global problem afflicting approximately 21% of the world’s population. It is the intermediate stage between normal glucose levels and type 2 diabetes mellitus (T2DM). Prediabetes is associated with major complications including the development of T2DM and increased cardiovascular disease (CVD). It can be easily diagnosed with an inexpensive plasma glucose level and/or a hemoglobin A1c (HbA1c) measurement. The mainstay of treatment is intensive lifestyle (ILS) intervention, including reduction in calories, especially saturated fats, refined carbohydrates, etc., coupled with regular physical activity of 150 min per week since ILS changes, with at least a 5% weight loss, have been shown to reduce progression to T2DM in multiple studies globally. Also, metformin therapy has been shown to prevent the progression to T2DM. In conclusion, serious consideration by guideline committees to classify prediabetes as a disease is highly recommended based on its global burden, easy and cost-effective diagnosis, association with serious conditions of diabetes and CVD, and effective ILS intervention. Therapy targeting those at an especially high risk for T2DM, such as persons with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) with values ≥ 110 mg/dL (6.1 mmol/L), and/or HbA1c ≥ 6.0% (42 mmol/mol) coupled with overweightness or obesity.
- 15 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 710
Open AccessShould Prediabetes Be Classified as a Treatable Disease?
Prediabetes is a serious and major global problem afflicting approximately 21% of the world’s population. It is the intermediate stage between normal glucose levels and type 2 diabetes mellitus (T2DM). Prediabetes is associated with major complications including the development of T2DM and increased cardiovascular disease (CVD). It can be easily diagnosed with an inexpensive plasma glucose level and/or a hemoglobin A1c (HbA1c) measurement. The mainstay of treatment is intensive lifestyle (ILS) intervention, including reduction in calories, especially saturated fats, refined carbohydrates, etc., coupled with regular physical activity of 150 min per week since ILS changes, with at least a 5% weight loss, have been shown to reduce progression to T2DM in multiple studies globally. Also, metformin therapy has been shown to prevent the progression to T2DM. In conclusion, serious consideration by guideline committees to classify prediabetes as a disease is highly recommended based on its global burden, easy and cost-effective diagnosis, association with serious conditions of diabetes and CVD, and effective ILS intervention. Therapy targeting those at an especially high risk for T2DM, such as persons with impaired glucose tolerance (IGT), impaired fasting glucose (IFG) with values ≥ 110 mg/dL (6.1 mmol/L), and/or HbA1c ≥ 6.0% (42 mmol/mol) coupled with overweightness or obesity.
- Open Access
- 9 October 2025
- Published by Scilight Press Pty Ltd in International Journal of Clinical and Translational Medicine
- Vol. 1 (4) , 1
A Review of Prediabetes: Diagnosis, Consequences and Interventions
Prediabetes describes a state of dysglycemia that is the “watershed” between normoglycemia and type 2 diabetes. This review will examine the definitions of prediabetes, the adverse complications of prediabetes, the treatment of prediabetes, and diabetes prevention.
- 9 October 2025
- Published by Scilight Press Pty Ltd in International Journal of Clinical and Translational Medicine
- Vol. 1 (4) , 1
Open AccessA Review of Prediabetes: Diagnosis, Consequences and Interventions
Prediabetes describes a state of dysglycemia that is the “watershed” between normoglycemia and type 2 diabetes. This review will examine the definitions of prediabetes, the adverse complications of prediabetes, the treatment of prediabetes, and diabetes prevention.
- Open Access
- 8 April 2025
- Published by Scilight Press Pty Ltd in International Journal of Clinical and Translational Medicine
- Vol. 1 (2) , 2
Practical Diagnosis of Iron Deficiency Anemia
Editorial Practical Diagnosis of Iron Deficiency Anemia William E. Winter 1 and Ishwarlal Jialal 2,*,† 1 Department of Pathology, University of Florida, Gainesville, FL 32611, USA 2 UC Davis School of Medicine, 2616 Hepworth Drive, Davis, CA 95618, USA * Correspondence: kjialal@gmail.com; Tel.: +1-530-902-0125 † Retired Distinguished Professor of Internal Medicine and Pathology. Received: 4 March 2025; Accepted: 12 March 025; Published: 8 April 2025
- 8 April 2025
- Published by Scilight Press Pty Ltd in International Journal of Clinical and Translational Medicine
- Vol. 1 (2) , 2
Open AccessPractical Diagnosis of Iron Deficiency Anemia
Editorial Practical Diagnosis of Iron Deficiency Anemia William E. Winter 1 and Ishwarlal Jialal 2,*,† 1 Department of Pathology, University of Florida, Gainesville, FL 32611, USA 2 UC Davis School of Medicine, 2616 Hepworth Drive, Davis, CA 95618, USA * Correspondence: kjialal@gmail.com; Tel.: +1-530-902-0125 † Retired Distinguished Professor of Internal Medicine and Pathology. Received: 4 March 2025; Accepted: 12 March 025; Published: 8 April 2025
- Open Access
- 7 November 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (6) , e004471
Identification of atypical pediatric diabetes mellitus cases using electronic medical records
Introduction: There are no established methods to identify children with atypical diabetes for further study. We aimed to develop strategies to systematically ascertain cases of atypical pediatric diabetes using electronic medical records (EMR). Research design and methods: We tested two strategies in a large pediatric hospital in the USA. Strategy 1: we designed a questionnaire to rule out typical diabetes and applied it to the EMR of 100 youth with diabetes. Strategy 2: we built three electronic queries to generate reports of three atypical pediatric diabetes phenotypes: unknown type, type 2 diabetes (T2D) diagnosed <10 years old and autoantibody-negative type 1 diabetes (AbNegT1D). Results: Strategy 1 identified six cases (6%) of atypical diabetes (mean diagnosis age=11±2.6 years, 16.6% men, 33% non-Hispanic white (NHW) and 66.6% Hispanic). Strategy 2: unknown diabetes type: n=68 (1%) out of 6676 patients with diabetes; mean diagnosis age=12.6±3.3 years, 32.8% men, 23.8% NHW, 47.6% Hispanic, 25.4% African American (AA), 3.2% other. T2D <10 years old: n=64 (6.6%) out of 1142 patients with T2D; mean diagnosis age=8.6±1.6 years, 20.3% men, 4.7% NHW, 65.6% Hispanic, 28.1% AA, 1.6% other. AbNegT1D: n=38 (5.6%) out of 680 patients with new onset T1D; mean diagnosis age=11.3±3.8 years; 57.9% men, 50% NHW, 19.4% Hispanic, 22.3% AA, 8.3% other. Conclusions: In sum, we identified 1%–6.6% of atypical diabetes cases in a pediatric diabetes population with high racial and ethnic diversity using systematic review of the EMR. Better identification of these cases using unbiased approaches may advance precision diabetes.
- 7 November 2024
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 12 (6) , e004471
Open AccessIdentification of atypical pediatric diabetes mellitus cases using electronic medical records
Introduction: There are no established methods to identify children with atypical diabetes for further study. We aimed to develop strategies to systematically ascertain cases of atypical pediatric diabetes using electronic medical records (EMR). Research design and methods: We tested two strategies in a large pediatric hospital in the USA. Strategy 1: we designed a questionnaire to rule out typical diabetes and applied it to the EMR of 100 youth with diabetes. Strategy 2: we built three electronic queries to generate reports of three atypical pediatric diabetes phenotypes: unknown type, type 2 diabetes (T2D) diagnosed <10 years old and autoantibody-negative type 1 diabetes (AbNegT1D). Results: Strategy 1 identified six cases (6%) of atypical diabetes (mean diagnosis age=11±2.6 years, 16.6% men, 33% non-Hispanic white (NHW) and 66.6% Hispanic). Strategy 2: unknown diabetes type: n=68 (1%) out of 6676 patients with diabetes; mean diagnosis age=12.6±3.3 years, 32.8% men, 23.8% NHW, 47.6% Hispanic, 25.4% African American (AA), 3.2% other. T2D <10 years old: n=64 (6.6%) out of 1142 patients with T2D; mean diagnosis age=8.6±1.6 years, 20.3% men, 4.7% NHW, 65.6% Hispanic, 28.1% AA, 1.6% other. AbNegT1D: n=38 (5.6%) out of 680 patients with new onset T1D; mean diagnosis age=11.3±3.8 years; 57.9% men, 50% NHW, 19.4% Hispanic, 22.3% AA, 8.3% other. Conclusions: In sum, we identified 1%–6.6% of atypical diabetes cases in a pediatric diabetes population with high racial and ethnic diversity using systematic review of the EMR. Better identification of these cases using unbiased approaches may advance precision diabetes.
- Open Access
- 4 March 2024
- Published by Wiley in Pediatric Diabetes
- Vol. 2024, 1-10
High Prevalence of A−β+ Ketosis-Prone Diabetes in Children with Type 2 Diabetes and Diabetic Ketoacidosis at Diagnosis: Evidence from the Rare and Atypical Diabetes Network (RADIANT)
Background. A−β+ ketosis-prone diabetes (KPD) in adults is characterized by presentation with diabetic ketoacidosis (DKA), negative islet autoantibodies, and preserved β-cell function in persons with a phenotype of obesity-associated type 2 diabetes (T2D). The prevalence of KPD has not been evaluated in children. We investigated children with DKA at T2D onset and determined the prevalence and characteristics of pediatric A−β+ KPD within this cohort. Methods. We reviewed the records of 716 children with T2D at a large academic hospital and compared clinical characteristics of those with and without DKA at onset. In the latter group, we identified patients with A−β+ KPD using criteria of the Rare and Atypical Diabetes Network (RADIANT) and defined its prevalence and characteristics. Results. Mean age at diagnosis was 13.72.4 years: 63 female; 59 Hispanic, 29 African American, 9 non-Hispanic White, and 3 other. Fifty-six (7.8) presented with DKA at diagnosis and lacked islet autoantibodies. Children presenting with DKA were older and had lower C-peptide and higher glucose concentrations than those without DKA. Twenty-five children with DKA (45) met RADIANT A−β+ KPD criteria. They were predominantly male (64), African American or Hispanic (96), with substantial C-peptide (1.30.7ng/mL) at presentation with DKA and excellent long-term glycemic control (HbA1c 6.61.9 at follow-up (median 1.3 years postdiagnosis)). Conclusions. In children with a clinical phenotype of T2D and DKA at diagnosis, approximately half meet criteria for A−β+ KPD. They manifest the key characteristics of obesity, preserved β-cell function, male predominance, and potential to discontinue insulin therapy, similar to adults with A−β+ KPD.
- 4 March 2024
- Published by Wiley in Pediatric Diabetes
- Vol. 2024, 1-10
Open AccessHigh Prevalence of A−β+ Ketosis-Prone Diabetes in Children with Type 2 Diabetes and Diabetic Ketoacidosis at Diagnosis: Evidence from the Rare and Atypical Diabetes Network (RADIANT)
Background. A−β+ ketosis-prone diabetes (KPD) in adults is characterized by presentation with diabetic ketoacidosis (DKA), negative islet autoantibodies, and preserved β-cell function in persons with a phenotype of obesity-associated type 2 diabetes (T2D). The prevalence of KPD has not been evaluated in children. We investigated children with DKA at T2D onset and determined the prevalence and characteristics of pediatric A−β+ KPD within this cohort. Methods. We reviewed the records of 716 children with T2D at a large academic hospital and compared clinical characteristics of those with and without DKA at onset. In the latter group, we identified patients with A−β+ KPD using criteria of the Rare and Atypical Diabetes Network (RADIANT) and defined its prevalence and characteristics. Results. Mean age at diagnosis was 13.72.4 years: 63 female; 59 Hispanic, 29 African American, 9 non-Hispanic White, and 3 other. Fifty-six (7.8) presented with DKA at diagnosis and lacked islet autoantibodies. Children presenting with DKA were older and had lower C-peptide and higher glucose concentrations than those without DKA. Twenty-five children with DKA (45) met RADIANT A−β+ KPD criteria. They were predominantly male (64), African American or Hispanic (96), with substantial C-peptide (1.30.7ng/mL) at presentation with DKA and excellent long-term glycemic control (HbA1c 6.61.9 at follow-up (median 1.3 years postdiagnosis)). Conclusions. In children with a clinical phenotype of T2D and DKA at diagnosis, approximately half meet criteria for A−β+ KPD. They manifest the key characteristics of obesity, preserved β-cell function, male predominance, and potential to discontinue insulin therapy, similar to adults with A−β+ KPD.
- 1 September 2023
- Vol. 53 (5) , 681-695
Iron Biology - An Overview for Laboratorians
Iron serves a critical role in many metabolic processes, including oxygen delivery (e.g., hemoglobin) and oxygen utilization for the generation of ATP (e.g., cytochromes). Disorders of iron metabolism are best recognized and evaluated in the context of iron's absorption, transportation, monitoring, cellular uptake, and recycling. This review highlights these processes so that disorders of iron deficiency and iron excess can be better understood. Key players in iron metabolism will be highlighted, such as hepcidin, ferroportin, erythroferrone, transferrin, ferritin, HFE, and the transferrin receptors.
- 1 September 2023
- Vol. 53 (5) , 681-695
Iron Biology - An Overview for Laboratorians
Iron serves a critical role in many metabolic processes, including oxygen delivery (e.g., hemoglobin) and oxygen utilization for the generation of ATP (e.g., cytochromes). Disorders of iron metabolism are best recognized and evaluated in the context of iron's absorption, transportation, monitoring, cellular uptake, and recycling. This review highlights these processes so that disorders of iron deficiency and iron excess can be better understood. Key players in iron metabolism will be highlighted, such as hepcidin, ferroportin, erythroferrone, transferrin, ferritin, HFE, and the transferrin receptors.
- 7 December 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 115, 3-12
Hematology and coagulation preanalytics for clinical chemists: Factors intrinsic to the sample and extrinsic to the patient
- 7 December 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 115, 3-12
Hematology and coagulation preanalytics for clinical chemists: Factors intrinsic to the sample and extrinsic to the patient
- 1 January 2022
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (1) , 197-205
Practical Clinical Applications of Islet Autoantibody Testing in Type 1 Diabetes
Background: The distinction between type 1 diabetes (T1D) and type 2 diabetes (T2D) is extremely important for the choice of therapy, body weight and dietary management, screening for coexistent autoimmune diseases and comorbidities, anticipated prognosis, and risk assessment in relatives. Not uncommonly, the presentation of the patient may not allow an unambiguous discrimination between T1D and T2D. To help resolve this challenge, the detection of islet autoantibodies can support the diagnosis of T1D. Content: The presence of islet autoantibodies in a person with diabetes indicates an autoimmune etiology therefore establishing the diagnosis of T1D. Presently 5 islet autoantibodies are available for routine clinical use: islet cell cytoplasmic autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibodies (GADA), insulinoma associated-2 autoantibodies (IA-2A), and zinc transporter-8 autoantibodies (ZnT8A). There are caveats to the selection of which islet autoantibodies should be measured. Islet autoantibodies can also predict the development of T1D. Therefore, once safe and effective therapies are available to prevent T1D, islet autoantibody testing is expected to become a routine part of medical practice. A very rare cause of autoimmune diabetes is the type B insulin resistance syndrome resulting from antagonistic autoantibodies to the insulin receptor. Rarely hypoglycemia can result from agonistic insulin receptor autoantibodies, or high-titer IAA causing the autoimmune insulin syndrome (i.e., Hirata disease). Summary: In summary, autoimmune causes of dysglycemia are increasing in clinical importance requiring the scrutiny of laboratorians. The determination of islet autoantibodies can greatly aid in the diagnosis and the prediction of T1D.
- 1 January 2022
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (1) , 197-205
Practical Clinical Applications of Islet Autoantibody Testing in Type 1 Diabetes
Background: The distinction between type 1 diabetes (T1D) and type 2 diabetes (T2D) is extremely important for the choice of therapy, body weight and dietary management, screening for coexistent autoimmune diseases and comorbidities, anticipated prognosis, and risk assessment in relatives. Not uncommonly, the presentation of the patient may not allow an unambiguous discrimination between T1D and T2D. To help resolve this challenge, the detection of islet autoantibodies can support the diagnosis of T1D. Content: The presence of islet autoantibodies in a person with diabetes indicates an autoimmune etiology therefore establishing the diagnosis of T1D. Presently 5 islet autoantibodies are available for routine clinical use: islet cell cytoplasmic autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibodies (GADA), insulinoma associated-2 autoantibodies (IA-2A), and zinc transporter-8 autoantibodies (ZnT8A). There are caveats to the selection of which islet autoantibodies should be measured. Islet autoantibodies can also predict the development of T1D. Therefore, once safe and effective therapies are available to prevent T1D, islet autoantibody testing is expected to become a routine part of medical practice. A very rare cause of autoimmune diabetes is the type B insulin resistance syndrome resulting from antagonistic autoantibodies to the insulin receptor. Rarely hypoglycemia can result from agonistic insulin receptor autoantibodies, or high-titer IAA causing the autoimmune insulin syndrome (i.e., Hirata disease). Summary: In summary, autoimmune causes of dysglycemia are increasing in clinical importance requiring the scrutiny of laboratorians. The determination of islet autoantibodies can greatly aid in the diagnosis and the prediction of T1D.